VENENUM Biodesign‘s ECLiPS collection of small molecule compounds contains large diverse discovery libraries. This collection is designed by experienced medicinal and computational chemists to maximize the probability for lead compound generation. Our ECLiPS collection is comprised of 5.5 million small molecules with drug-like properties. It is a proven deck for HTS with a success rate of ~70% across pharmaceutical targets including GPCRs, enzymes, NHRs, transporters, and ion channels.
The ECLiPS technology is an integrated solid-phase synthesis and screening technology implemented by Pharmacopeia. ECLiPS was used successfully by Pharmacopeia to identify hits, drive lead optimization, and nominate Development Candidates (DC) in collaborations with multiple pharmaceutical and biotech companies. Ligand Pharmaceuticals acquired Pharmacopeia in 2008, and Venenum Biodesign acquired the ECLiPS technology from Ligand Pharmaceuticals in 2010. Venenum Biodesign has used ECLiPS to develop its own drug discovery pipeline. The Venenum Biodesign business model is to partner its programs at, or near DC, thus allowing Venenum Biodesign to concentrate on the discovery of new targets and new chemical entities.
Venenum Biodesign has continued to construct new libraries to target challenging protein – protein interactions (PPI) and protein–DNA interactions (PDI). Venenum Biodesign chemists and molecular modelers have designed and synthesized a series of new libraries aimed at these challenging targets. Both the Venenum Targeted Libraries (sets of 500-700 compounds) and larger (20,000- 30,000 compounds) ECLiPS libraries have been synthesized based on in-house design ideas.